DSC Advisors’s Adverum Biotechnologies ADVM Stock Holding History

DSC Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,613	Closed	-$424K	–	65
2015 Q2	$424K	Buy	+2,613	New	+$882K	0.22%	46

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

DSC Advisors's ADVM Position: Q3 2015 in Review

DSC Advisors sold out of Adverum Biotechnologies (ADVM) in Q3 2015, closing a stake of 2,613 shares — an estimated $424K sold.

DSC Advisors first reported a position in ADVM in Q2 2015 and held it in 1 quarter. The position peaked at $424K in Q2 2015. 92 funds tracked by Wall St. Rank hold ADVM as of Q3 2015.

DSC Advisors reported no remaining Adverum Biotechnologies position as of Q3 2015 after selling out during the quarter.
DSC Advisors sold 2,613 Adverum Biotechnologies shares in Q3 2015, an estimated $424K.
DSC Advisors first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 1 quarter.
DSC Advisors's Adverum Biotechnologies position peaked at $424K in Q2 2015.
92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2015.

Based on DSC Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.